93 related articles for article (PubMed ID: 12392102)
1. Cancer chemotherapy by liposomal 6-[12-(dimethylamino)ethyl]aminol-3-hydroxy-7H-indeno[2,1-clquinolin-7-one dihydrochloride (TAS-103), a novel anti-cancer agent.
Shimizu K; Takada M; Asai T; Kuromi K; Baba K; Oku N
Biol Pharm Bull; 2002 Oct; 25(10):1385-7. PubMed ID: 12392102
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.
Aoyagi Y; Kobunai T; Utsugi T; Wierzba K; Yamada Y
Jpn J Cancer Res; 2000 May; 91(5):543-50. PubMed ID: 10835500
[TBL] [Abstract][Full Text] [Related]
4. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
[TBL] [Abstract][Full Text] [Related]
5. A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells.
Ohyama T; Li Y; Utsugi T; Irie S; Yamada Y; Sato T
Jpn J Cancer Res; 1999 Jun; 90(6):691-8. PubMed ID: 10429663
[TBL] [Abstract][Full Text] [Related]
6. In vitro antitumor activity of TAS-103 against freshly-isolated human colorectal cancer.
Tsunoda T; Tanimura H; Yamaue H; Ishimoto K; Kobunai T; Yamada Y
Anticancer Res; 2001; 21(6A):3897-902. PubMed ID: 11911266
[TBL] [Abstract][Full Text] [Related]
7. Promising antitumor activity of a novel quinoline derivative, TAS-103, against fresh clinical specimens of eight types of tumors measured by flow cytometric DNA analysis.
Fujimoto S
Biol Pharm Bull; 2007 Oct; 30(10):1923-9. PubMed ID: 17917263
[TBL] [Abstract][Full Text] [Related]
8. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
Sunami T; Nishio K; Kanzawa F; Fukuoka K; Kudoh S; Yoshikawa J; Saijo N
Cancer Chemother Pharmacol; 1999; 43(5):394-401. PubMed ID: 10100595
[TBL] [Abstract][Full Text] [Related]
9. A new mechanism of 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride (TAS-103) action discovered by target screening with drug-immobilized affinity beads.
Yoshida M; Kabe Y; Wada T; Asai A; Handa H
Mol Pharmacol; 2008 Mar; 73(3):987-94. PubMed ID: 18089836
[TBL] [Abstract][Full Text] [Related]
10. Self-association and unique DNA binding properties of the anti-cancer agent TAS-103, a dual inhibitor of topoisomerases I and II.
Ishida K; Asao T
Biochim Biophys Acta; 2002 Jul; 1587(2-3):155-63. PubMed ID: 12084457
[TBL] [Abstract][Full Text] [Related]
11. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer.
Tomoda K; Ohkoshi T; Hirota K; Sonavane GS; Nakajima T; Terada H; Komuro M; Kitazato K; Makino K
Colloids Surf B Biointerfaces; 2009 Jul; 71(2):177-82. PubMed ID: 19264458
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM
Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
14. Potential usage of liposomal 4beta-aminoalkyl-4'-O-demethyl-4-desoxypodophyllotoxin (TOP-53) for cancer chemotherapy.
Shimizu K; Takada M; Asai T; Irimura K; Baba K; Oku N
Biol Pharm Bull; 2002 Jun; 25(6):783-6. PubMed ID: 12081147
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
Ewesuedo RB; Iyer L; Das S; Koenig A; Mani S; Vogelzang NJ; Schilsky RL; Brenckman W; Ratain MJ
J Clin Oncol; 2001 Apr; 19(7):2084-90. PubMed ID: 11283142
[TBL] [Abstract][Full Text] [Related]
16. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent.
Miatmoko A; Kawano K; Yoda H; Yonemochi E; Hattori Y
J Liposome Res; 2017 Jun; 27(2):99-107. PubMed ID: 26982164
[TBL] [Abstract][Full Text] [Related]
17. In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II.
Aoyagi Y; Kobunai T; Utsugi T; Oh-hara T; Yamada Y
Jpn J Cancer Res; 1999 May; 90(5):578-87. PubMed ID: 10391099
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
19. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]